Focus: AVITA Medical develops autologous skin cell harvesting and treatment devices for dermatological applications, primarily in burn care and wound management. The company operates as a device-focused biotech with a concentrated portfolio in regenerative dermatology.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Stable — net -3 jobs in 30d
0 added, 3 removed. Backfill posture.
AVITA is a specialized dermatology device company with a single near-commercialization asset; suitable for candidates seeking deep device expertise but risky for those prioritizing career optionality or rapid growth.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Phase 4 program with 15 active trials representing the company's lead commercial asset in burn care.
Help build intelligence for AVITA Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AVITA Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+2 more
Avita Medical (RCEL) Q1 Loss Of US$0.35 Per Share Tests Profitability Optimism - simplywall.st
Avita Medical (RCEL) Q1 Loss Of US$0.35 Per Share Tests Profitability Optimism simplywall.st
Competitive Analysis: Leading Companies and New Entrants in the Scar Treatment Market - openPR.com
Competitive Analysis: Leading Companies and New Entrants in the Scar Treatment Market openPR.com
Daily Special: Hiremii, Immutep, AVITA Medical, Southern Palladium - Finance News Network
Daily Special: Hiremii, Immutep, AVITA Medical, Southern Palladium Finance News Network
Scar Treatment Market to Reach US$ 49.2 Bn by 2033 Expands Amid Rising Aesthetic Demand and Technological Innovation - Persistence Market Research - PR Newswire UK
Scar Treatment Market to Reach US$ 49.2 Bn by 2033 Expands Amid Rising Aesthetic Demand and Technological Innovation - Persistence Market Research PR Newswire UK
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles